Spinal cord atrophy measured from cerebral T1-weighted MRI: applications in clinical investigations of neuromyelitis optica spectrum disorders by Chien, Claudia
 
Aus dem NeuroCure Clinical Research Center der 




Spinal cord atrophy measured from cerebral T1-weighted 
MRI: applications in clinical investigations of 




zur Erlangung des akademischen Grades 







































































Table of Contents 
 
          Page Number 
 
1. Synopsis           
1.1 Abstract (English)        1  
1.2 Abstract (Deutsch)        2 – 3  
1.3 Introduction         4 – 6  
1.4 State of Research        6 – 8   
1.5 Materials and Methods       8 – 12  
1.6 Results         12 – 15   
1.7 Conclusions and Future Directions      15 – 16   
1.8 References         17 – 20  
 
2. Affidavit/Statutory Declaration       21 
 
3. Declaration of contributions to the publications     22  
 
4. Print versions of the selected publications     23 
4.1 Publication 1         24 – 30   
4.2 Publication 2         31 – 41 
4.3 Publication 3         42 – 50 
  
5. Curriculum Vitae         51 – 52  
 
6. Complete List of Publications       53 – 55   
 





































1.1 Abstract (English) 
Magnetic resonance imaging (MRI) is used extensively for differential diagnosis and disease 
monitoring in neuroinflammatory disorders. Neuromyelitis optica spectrum disorders 
(NMOSD) are autoimmune neuroinflammatory diseases of the central nervous system that 
affect mainly the optic nerves, and spinal cord (SC). SC MRI shows longitudinally extensive 
transverse myelitis in the vast majority of NMOSD patients, where chronic inflammation 
leads to SC lesions and SC atrophy. In vivo imaging biomarkers are lacking for these 
patients, which could greatly aid in evaluating treatment efficacy or monitoring disease-
related changes. 
The key questions addressed in my dissertation are: 
1. Can cerebral T1-weighted MRI be used to measure SC atrophy in NMOSD? 
2. Is there a difference in SC affection between aquaporin-4 IgG seropositive (AQP4-
IgG+) and myelin oligodendrocyte glycoprotein IgG seropositive (MOG-IgG+) 
NMOSD patients? 
3. Is spinal cord atrophy associated with damage in thalamic subregions of AQP4-IgG+ 
patients with myelitis? 
Cervical cord volume, total cord volume, and mean upper cervical cord area (MUCCA) were 
compared and demonstrated the ability to discriminate between AQP4-IgG+ NMOSD 
patients and healthy participants. MUCCA, measured from cerebral T1-weighted MRIs, 
correlated well with cervical cord and total cord volumes, even in patients. SC atrophy 
measurements using MUCCA were thus shown to accurately reflect damage in the entire SC 
of AQP4-IgG+ NMOSD patients. The SC lesion prevalence in specific locations and the 
mean MUCCA between the NMOSD antibody subgroups were similar. However, AQP4-
IgG+ patients had more myelitis attacks, SC lesions, and SC atrophy than MOG-IgG+ 
patients. MUCCA associated with clinical attacks and disability in both NMOSD subgroups 
combined. Damage to the ventral posterior nucleus of the thalamus in AQP4-IgG+ patients 
with myelitis attacks were tested for association with MUCCA. This assessment of mutual 
damage/atrophy was negative. In summary, these studies proved that SC atrophy can be 
assessed using MUCCA, increases in NMOSD patients with more myelitis attacks, and that 
MUCCA is a valuable in vivo imaging parameter in NMOSD. These findings will be crucial 
in future clinical studies that monitor or evaluate treatment efficacy of patients with 




1.2 Abstract (Deutsch) 
 
Die Magnetresonanztomographie (MRT) ist eine wichtige Methode für die 
Differentialdiagnose und das Monitoring neuroinflammatorischer Erkrankungen. Bei 
Neuromyelitis optica Spektrum-Erkrankungen (NMOSD) handelt es sich um eine Gruppe 
autoimmuner, inflammatorischer Erkrankungen des zentralen Nervensystems, die vor allem 
die Sehnerven und das Rückenmark betreffen. Mittels spinaler MRT kann bei einer 
überwiegenden Mehrheit der NMOSD Patienten eine longitudinale extensive transverse 
Myelitis nachgewiesen werden. Zur Beobachtung krankheitsbedingter Veränderungen in 
diesen Patienten und zur Therapieevaluation fehlen in-vivo bildgebende Biomarker.  
Die vorliegende Dissertation behandelt drei zentrale Fragen anhand von Studien:  
1. Eignen sich zerebrale T1-gewichtete MRT Aufnahmen, um die Rückenmarkatrophie 
bei NMOSD Patienten zu quantifizieren? 
2. Gibt es Unterschiede zwischen Aquaporin-IgG-seropositiven (AQP4-IgG+) und 
Myelin-Oligodendrozyten-Glykoprotein (MOG-IgG+) NMOSD Patienten im 
Hinblick auf die Myelonaffektion?  
3. Besteht bei AQP4-IgG+ Patienten mit Myelitis ein Zusammenhang zwischen 
Atrophie im Rückenmark und Schäden in Teilregionen des Thalamus? 
Sowohl das Zervikalmarksvolumen, das gesamte Rückenmarksvolumen als auch die mittlere 
Querschnittsfläche des oberen Zervikalmarks (“mean upper cervical cord area”, 
MUCCA) zeigten signifikante Unterschiede zwischen AQP4-IgG+ NMOSD Patienten und 
gesunden Probanden. MUCCA, gemessen mittels zerebralen T1-gewichteten MRTs, 
korreliert gut mit den zuvor genannten Volumina, auch in NMOSD-Patienten. Die 
Quantifizierung von Rückenmarkatrophie mittels MUCCA ist daher geeignet, um Schäden 
im gesamten Rückenmark in AQP4-IgG+ NMOSD Patienten erfassen. Die Prävalenz von 
SC-Läsionen an bestimmten Lokationen und den MUCCA-Mittelwerten zwischen den 
NMOSD-Antikörper-Patientengruppen waren ähnlich. Im Vergleich zu MOG-IgG+ Patienten 
erleiden AQP4-IgG+ Patienten häufig mehr Myelitisschübe, Rückenmarksläsionen, und 
Rückenmarksatrophie. MUCCA korreliert mit der Anzahl der Krankheitsschübe und 
Behinderung für beide NMOSD Patientengruppen zusammen betrachtet. Eine Betrachtung 
der Schäden im Nucleus ventralis posterior des Thalamus in AQP4-IgG+ Patienten mit 
Myelitisschüben ergab keine Korrelationen mit MUCCA. Zusammenfassend konnte daher 
gezeigt werden, dass Rückenmarksatrophie mittels MUCCA gemessen werden kann, in 




in-vivo bildgebenden Biomarker darstellt. Diese Ergebnisse werden in der Durchführung 
zukünftiger klinischer Studien zur Beobachtung und Evaluierung von Therapien bei Patienten 



















































Neuromyelitis optica spectrum disorders (NMOSD) are a group of rare autoimmune disorders 
of the central nervous system (CNS), where patients commonly present with optic neuritis, 
myelitis, and more rarely, brainstem and cerebral attacks [1]. Originally thought to be a 
subset of multiple sclerosis (MS), and often called Devic’s Disease, its designation as a 
disease distinct from MS can be attributed to the finding that a pathogenic immunoglobulin-G 
specific for aquaporin-4 water channel protein is present in the serum of ~70% of patients 
(AQP4-IgG+) [2,3]. AQP4-IgG acts on astrocytic foot processes in CNS regions rich in 
AQP4 protein, such that demyelination is not the first inflammatory consequence in these 
NMOSD patients [4]. Some AQP4-IgG seronegative NMOSD patients are seropositive for 
antibodies against myelin-oligodendrocyte-glycoprotein (MOG-IgG+) [5]. MOG-IgG acts on 
oligodendrocytes, leading to both oligodendrocyte and myelin damage in the CNS of these 
patients, thus, complicating research into NMOSD patients further [6]. 
Although there are different immunological mechanisms in NMOSD patients that are AQP4-
IgG+ versus MOG-IgG+, spinal cord (SC) affection, in the form of longitudinally extensive 
transverse myelitis (LETM), is common in both NMOSD phenotypes [7–9]. LETM can be 
seen as T2-hyperintense lesions in SC MRIs, spanning greater than 3 vertebral segments in 
about 85 – 90% of AQP4-IgG+ patients [10]. Chronic LETM or acute and/or shorter lesions 
can subsequently cause SC atrophy [11]. SC affection is a major component in patient 
prognosis, where length of myelitis-lesions have been shown to be associated with long-term 
disability in AQP4-IgG+ patients [12]. NMOSD myelitis attacks are often severe with 
incomplete recovery [10], thus it would be beneficial to these patients if there was an easy, 
reliable, in vivo method for measuring and monitoring SC atrophy. As a consequence, SC 
atrophy is increasingly being investigated in neuroinflammatory diseases by way of magnetic 
resonance imaging (MRI) [13]. 
One of the most common methods of SC atrophy measurement is the mean upper cervical 
cord area (MUCCA) [14]. Although MUCCA has been used in MS studies, there is no 
consensus on a particular method in calculating this measure and which MRI sequence to use. 
Selection of MRI sequence, as well as methods for analysis of SC atrophy need to be 
considered carefully during the planning stage of a prospective study, especially those 
involving limited MRI sessions or patients (e.g. in the case of rare diseases). MUCCA 
calculated from different MRI sequences or using different regions of the cord would likely 




planning of multi-centered studies or clinical measurement of MUCCA, as this could lead to 
incorrect conclusions.  
Since there are different immunological aspects to this disease, there are currently no 
established imaging biomarkers in NMOSD for monitoring disease stage or severity, or 
which measures could serve as outcomes in clinical trials [16]. SC MRI could lead to a 
clinically relevant imaging outcome measure in NMOSD, since lesions/LETM (location and 
length) can be seen using T2-weighted SC specific MRI [10]. Meanwhile, to measure atrophy 
of the SC, MUCCA calculated from T1-weighted cerebral MRIs [17,18] can be used, 
however, further evaluation of conventional SC MRI methods are required in NMOSD. This 
dissertation details the studies conducted to answer several important questions in relation to 
SC atrophy measurement and its application in clinical investigations of NMOSD patients. 
 
1.3.1 Questions and Hypotheses 
Three studies were conducted to answer the following research questions. 
1. Can cerebral T1-weighted MRI be used to measure SC atrophy in NMOSD? 
In Study 1 [19] of this dissertation, it was hypothesized that MUCCA, measured from 
T1-weighted cerebral MRI, is robust and reflects the SC atrophy or damage in the 
entire spinal cord, therefore simplifying SC atrophy evaluation with respect to 
acquisition and measurement. We also tested whether different SC MRI measures 
could discriminate between healthy participants and NMOSD patients to further 
evaluate the clinical feasibility of using SC measurements to investigate disease-
related structural damage in this set of diseases. 
 
2. Is there a difference in SC affection between aquaporin-4 IgG seropositive (AQP4-
IgG+) and myelin oligodendrocyte glycoprotein IgG seropositive (MOG-IgG+) 
NMOSD patients? 
Since the target of AQP4-IgG are mainly at the foot-processes of astrocytes, it would 
be expected that structural damage would be more severe in this disease subgroup. 
While MOG-IgG targets oligodendrocytes, it would be expected that myelin damage 
is the primary source of affection in these patients, which may not immediately 
present as atrophy in the CNS. Thus, the hypothesis in Study 2 [20] of this 
dissertation was that there would be a difference between AQP4-IgG+ and MOG-





3. Is there simultaneous atrophy in the ventral posterior nuclei of the thalamus and SC in 
AQP4-IgG+ NMOSD patients with myelitis? 
The thalamus has been found to be affected in neuroinflammatory diseases, such as 
multiple sclerosis, and since it receives and sends signals to many regions of the CNS, 
it has been proposed as an imaging marker in NMOSD as well. Thus, to evaluate 
whether NMOSD-related myelitis attacks are causing damage locally, or are able to 
spread to different regions of the CNS that are highly connected functionally and 
structurally to the spinal cord, MUCCA and thalamic volume were measured and 
compared.  It was hypothesized in Study 3 [21] of this dissertation that the ventral 
posterior nucleus (VPN) of the thalamus would be atrophied at the same time and 
associate with SC atrophy due to myelitis. 
 
1.4 State of Research 
1.4.1 Spinal Cord Atrophy – MRI Context 
Most studies on SC atrophy in NMOSD have focused on the measurement of cervical cross-
sectional area. This is likely due to two reasons: 1) NMOSD lesions are most prevalent in the 
cervical and upper thoracic spinal cord [13] and 2) these measurements can be performed 
relatively simply. For example, it is possible to measure this parameter using a short MRI 
axial spine sequence. Furthermore, a 3D magnetization prepared rapid gradient echo 
(MPRAGE) MRI sequence of the brain, including the upper cervical cord (UCC), is able to 
give good agreement between MUCCA values in multi-centered studies [18]. Full or 
dedicated SC MRI scanning requires a significant amount of additional time and costs for 
patient visits. Complex analysis methods for the quantification of SC measures further 
decrease the availability of full SC evaluation in clinical routine. New sequences are 
available for SC myelin content or functional assessment in patients, but due to the 
experimental nature of the scanning and analysis, it has been difficult to implement into 
normal clinical routine [22]. 
However, the additional benefit of full SC evaluation, using commonly acquired 2D SC MRI, 
over a simple MUCCA measurement from cerebral MRIs was not previously investigated. 
The use of cerebral 3D MRIs with the UCC as a source for MUCCA calculations was chosen 
for Study 1 of this dissertation because many centers use this sequence to regularly image 
patients for detection of abnormalities in the brain. Both cerebral MPRAGE and T2-weighted 
full SC MRIs had been collected cross-sectionally in a relatively large cohort of AQP4-IgG+ 




atrophy. Therefore, full cervical cord and full cord volumes could be compared to MUCCA 
in an age- and sex-matched cohort, allowing for evaluation of MUCCA in detecting SC 
atrophy and discriminating between HC and NMOSD patients [19]. 
 
1.4.2 Spinal Cord Atrophy – Clinical Context 
Myelitis, presenting in the form of LETM, has been reported in both patients with AQP4-
IgG+ and MOG-IgG+ autoimmunity and is a common clinical NMOSD phenotype [23]. 
Acute and radiologically visible extensive SC inflammation and concurrent clinical myelitis 
attacks can subsequently cause SC atrophy [11]. SC atrophy measurements, especially 
MUCCA, are reduced in AQP4-IgG+ NMOSD compared to HC and lower MUCCA have 
been shown to be associated with worse clinical disability [13,24]. Quantification of SC 
damage is also becoming an important method to further investigate pathomechanisms in the 
different NMOSD subtypes [25]. However, large cohorts of NMOSD patients with definite 
AQP4-IgG and MOG-IgG seropositivity, identified with cell-based assays, were not 
previously compared in the context of SC affection by myelitis/LETM, lesions or atrophy. In 
Study 2 of this dissertation, we used SC specific MRI sequences to evaluate SC lesion 
lengths and locations, as well as cerebral MPRAGE MRI to measure MUCCA in AQP4-
IgG+ and MOG-IgG+ NMOSD patients against HC [20]. 
 
1.4.3 Spinal Cord Atrophy – Non-focal Damage 
Assessment of distal CNS regions from localized attacks has not been performed in this 
complex disease. The thalamus has been shown to be a major hub for inputs from sensory 
pathways (e.g. from the spinal cord) and subcortical regions of the brain, as well as from the 
cortex [26]. Atrophy of the total thalamus has been investigated with varied findings in 
NMOSD, where some groups have found total thalamic atrophy with clinical disability 
associations while others have not [27,28]. This could be due to differences in cohort 
selection, methods, or true differences in patient cohorts due to demographics. However, an 
in-depth investigation of the thalamic subregions has not been thoroughly performed in 
AQP4-IgG+ NMOSD patients. Especially in AQP4-IgG+ NMOSD, where the optic nerves 
and spinal cord (SC) are the primary sites of damage when patients present with an optic 
neuritis or myelitis attack [1], could evaluation and monitoring of these small regions be 
clinically relevant.  
In this way, an association of the ventral posterior nuclei (VPN) of the thalamus with 




local attack regions to the thalamus. In Study 3 of this dissertation, we assessed the 
association of MUCCA, as a measure of SC atrophy, with VPN volume in patients compared 
to HC [21]. 
 
1.4.4 Objectives 
This dissertation aimed to translate SC MRI methods to NMOSD research and to bridge the 
technical and clinically relevant applications of these methods. This involved the validation 
of using a common cerebral MRI sequence for SC atrophy measurements, representative of 
full SC damage. The validated method was then applied to studies which evaluated and 
elucidated new information on SC atrophy and affection in NMOSD patients. The 
overarching goal of this research is to have an MRI biomarker, which can easily be 
implemented using common clinical MRI scans and is indicative of and/or can be used to 
monitor NMOSD patient disability severity and extent of tissue damage.  
 
1.5 Materials and Methods 
This section gives an overview of the main MRI techniques utilized in this dissertation. 
Specific study methodologies, including study design, patient demographics and selection 
criteria, image analysis, and statistical analysis are described in full in the attached original 
publications [19–21].  
All data were derived from two retrospective, observational, ongoing studies: the 
Neuromyelitis Optica (NMO) study and the Visual Imaging Multiple Sclerosis (VIMS) study 
at the NeuroCure Clinical Research Center (NCRC), Charité-Universitätsmedizin Berlin 
(EA1/041/14 and EA1/163/12). All studies were approved by the ethics committee of the 
Charité-Universitätsmedizin Berlin. All MRI scanning was performed on a 3T Siemens Tim 
Trio machine at the Berlin Center for Advanced Neuroimaging (BCAN), across from the 
NCRC in the Charité-Campus Mitte. Patients gave written informed consent to participate in 
the studies. After validation and peer-reviewed publications using the MUCCA analysis 
technique, MUCCA is now incorporated into all observational studies within the routine post-
processing pipelines. 
 
1.5.1 Evaluation of MUCCA as a surrogate measure for cervical and full spinal cord 
atrophy in AQP4-IgG+ NMOSD patients 
Spinal cord (SC) changes and involvement have been shown to be an important factor in 




multiple sclerosis (MS) [29,30]. Due to the nature of MRI, there are limitations in the 
sensitivity and specificity when imaging and analyzing the SC, especially in disease-states 
that are not clearly understood, such as in NMOSD. This objective was addressed in the first 
publication (Study 1) within this dissertation [19]. In MS, patients often have decreased SC 
cross-sectional areas as measured by MRI, that indicates axonal degeneration, which is a 
secondary effect in the disease after demyelination [31]. However, in aquaporin-4 
immunoglobulin-G seropositive (AQP4-IgG+) NMOSD patients, it is thought that disease-
related attacks and lesions are caused by a primary astrocytopathy [32], thus it is unknown 
whether short-term/cross-sectional analysis of SC cross-sectional areas are able to detect 
changes in these patients.  
To show that measuring the mean upper cervical cord area (MUCCA) from cerebral MRI 
scans is a reliable and representative measure of SC atrophy in NMOSD, we conducted Study 
1 with 30 AQP4-IgG+ NMOSD patients and 19 healthy controls. We used 2D T2-weighted 
SC MRI sequences to calculate cervical cord and full SC volumes, while 3D T1-weighted 
magnetization prepared rapid acquisition of gradient echo (MPRAGE) brain scans including 
the upper cervical cord were used to calculate MUCCA.  
Total cord volume (TCV) was measured from SC MRIs at 3 different levels: cervical, 
thoracic, and lumbar. The volumetric analysis of the full SC required the addition of 3 
segments measured from: 1) the tip of the dens to the rostral border of the thoracic (T)1 
vertebral body, 2) the rostral border of the T1 vertebral body to the T11 vertebral body rostral 
border, and 3) the T11 vertebral body rostral border to the conus tip. Figure 1 [19], shows 
sample segmentations of MUCCA, cervical cord volume (CCV), and representative 
segmentations of the thoracic and lumbar SC. 
 
Figure 1. Sample segmentation of A) MUCCA from a T1-weighted cerebral MPRAGE 
sequence, B) cervical cord volume, C) the thoracic SC volume, and D) the lumbar SC volume 
calculated from T2-weighted SC sequences. The total cord volume is calculated from the sum 





Group differences in discrete measures were tested with a Chi-squared test, while for 
continuous measurements (i.e. age, MUCCA, CCV, TCV) a two-sampled t-test was used. 
MUCCA, CCV, and TCV correlations with each other and with parametric clinical measures, 
such as averaged timed 25-foot walk and dominant and nondominant hand 9-hole peg test 
times were tested using a Pearson’s correlation test. Correlations with discrete measures were 
analyzed with a Spearman rank correlation test. Performance of each SC measure was 
evaluated using receiver operating characteristic analysis for the detection of NMOSD versus 
HC SC measures.  
 
1.5.2 Evaluation of SC affection in AQP4-IgG+ versus MOG-IgG+ NMOSD patients  
Autoantibodies against aquaporin-4 (AQP4) water channel proteins mainly target astrocytes, 
the choroid plexus epithelial cells and possibly Müller cells in the retina. Meanwhile, 
autoantibodies against myelin oligodendrocyte glycoprotein (MOG) predominantly attach to 
the outermost layers of myelin sheaths [33]. Recently, there have been many discussions over 
whether or not MOG-IgG+ patients should be categorized as having NMOSD at all [34,35]. 
Nevertheless, studies have found similar pathological features regarding SC involvement and 
clinical manifestations in both patients seropositive for AQP4-IgG and MOG-IgG [9]. 
However, validation of differences in SC affection and their clinical impact between the two 
antibody subgroups of patients with NMOSD have not previously been assessed. This was 
most likely caused by the relatively new diagnostic criteria for NMOSD, including lack of 
availability and costs for MOG-IgG cell-based assays [1,36]. This objective was addressed in 
the second publication (Study 2) within this dissertation. Several clinical measures may affect 
the SC atrophy observed in NMOSD: the number of clinical myelitis attacks and the time 
since last myelitis attack. Since it is hypothesized that severe acute clinical attacks in 
NMOSD are the cause of immediate axonal destruction within lesions [9,37], it is pertinent to 
explore this theme further by looking at atrophy measures in relation to the time since a last 
myelitis attack.  
In Study 2 [20], we endeavoured to evaluate and validate differences between AQP4-IgG+ 
and MOG-IgG+ NMOSD (cell-based assay serostatus confirmed) patient SC abnormalities 
by recording T2-hyperintense SC lesion locations, length, and counts. We also calculated the 
mean upper cervical cord area (MUCCA), as a measure of SC atrophy, in each patient 
subgroup and compared these measures with age- and sex-matched healthy controls (HC). 
Clinical manifestation was tested for correlations with MUCCA, using disease duration, 




pyramidal function score (a section of the Neurostatus EDSS score [38]), the timed 25-foot 
walk test times, and 9-hole peg test times. A total of 53 NMOSD (AQP4-IgG+ n = 38; MOG-
IgG+ n = 15) patients were included in the study. The MRIs utilized in this study included a 
2D T2-weighted SC sequence to visualize and calculate SC lesions locations, lengths, and 
counts, and a T1-weighted 3D MPRAGE brain MRI including the upper cervical cord for 
MUCCA measurement. 
SC lesion counts and median lesion lengths were analyzed for differences using Chi-square 
tests, while MUCCA group differences between HC and NMOSD patients were calculated 
using Welch’s two-sample t-test. Correlations between clinical myelitis attack numbers and 
weeks since last myelitis with MUCCA, were performed using Spearman’s rho estimate. 
Clinical manifestations of SC atrophy were evaluated using age and head-size as covariates 
with parametric multivariable linear models. 
 
1.5.3 Myelitis attack related changes in the ventral posterior thalamic nuclei in association 
with MUCCA of AQP4-IgG+ NMOSD patients 
Although normal (non-atrophied) deep grey matter volumes have been seen in NMOSD 
patients compared to healthy controls [28], it has not been investigated previously whether 
subtle changes are occurring in subregions of the thalamus. This objective was addressed in 
the third publication (Study 3) within this dissertation [21]. Due to recent advances in MRI 
analysis methods, there are now advanced 3D atlases based on histological data, which fit 
each anatomical region of the basal ganglia, including subregions (nuclei) of the thalamus 
[39]. Since the thalamus is connected to cortical regions [26], and several nuclei of this basal 
ganglia component receive direct signals from the visual and spinothalamic pathways [40], it 
would be expected that any anterograde or retrograde degeneration along these tracks would 
be seen in these structures. Evaluation of damage from myelitis in the non-localized region of 
the ventral posterior nucleus (VPN) of the thalamus would allow for evaluation of this type of 
degeneration. 
In Study 3, we performed a cross-sectional analysis of 39 patients with AQP4-IgG+ NMOSD 
and 37 age- and sex-matched healthy controls (HC). 3 Tesla T1-weighted 3D magnetization 
prepared rapid gradient echo (MPRAGE) brain including the upper cervical cord was used 
for mean upper cervical cord area (MUCCA) calculation. T2-hyperintense lesion masks were 
made with T2-weighted 3D fluid attenuated inversion recovery (FLAIR) brain MRIs, which 
allowed for lesion-infilling of brain lesion voxel intensities in each patient MPRAGE scan. 




matter, in the event that lesions are in and around these structural brain components. The 
Multiple Automatically Generated Templates Brain Segmentation Algorithm (MAGeTbrain, 
http://cobralab.ca/software/MAGeTbrain/) was used for segmentation of the thalamus and its 
subregions in each individual participant MRI scan, giving volumes for the VPN. 
Associations of VPN volumes with demographic, clinical, and MUCCA measures were 
evaluated using linear mixed effect models (LMM), with inter-side and intra-participant 
dependencies, adjusting for age and sex as fixed effects.  
 
1.6 Results 
1.6.1 Evaluation of MUCCA as a surrogate measure for cervical and full spinal cord 
atrophy in AQP4-IgG+ NMOSD patients  
In Study 1 [19], we demonstrated that all 3 types of SC quantification could be used to 
differentiate between age- and sex-matched HC (n = 19) and AQP4-IgG+ NMOSD patients 
(n = 30), where all measures were significantly dependent on each other. Receiver operating 
characteristic analysis was used for evaluating accuracy and sensitivity in each measure’s 
ability to discriminate between HC and NMOSD, which showed similar areas under the 
curve (Figure 2). Table 1 illustrates how all 3 SC quantification methods show statistically 
different measures between HC and patients (adapted from Table 2 in Chien et al. AJNR, 
2018 [19]) using two-sampled t-tests 
Mean upper cervical cord area (MUCCA), the cervical cord volume, and total cord volume 
did not correlate with clinical disability, as measured by the expanded disability status scale, 
the pyramidal functional system score, and the averaged timed 25-foot walk and 9-hole peg 
tests. 
 
Table 1 | Quantitative SC MRI measures  
SC Measure Healthy Controls 
(mean ± SD) 
AQP4-IgG+ NMOSD  
patients 







73.3 ± 5.51 
 
68.5 ± 7.06 2.70; .009* 
CCV (mL) 
 
7.52 ± 0.92 
 
6.61 ± 0.96 3.33; .002* 
TCV (mL) 20.1 ± 2.37 17.6 ± 2.21 
 
3.69; <.001* 
NMOSD = neuromyelitis optica spectrum disorders; MUCCA = mean upper cervical cord area; CCV = cervical 
cord volume; TCV = total cord volume; SD = standard deviation; *=statistical difference from healthy subjects 





Figure 2. Receiver operating characteristics showing the discriminatory power of the mean 
upper cervical cord area, cervical cord volume, and total cord volume for identification of 
AQP4-IgG+ NMOSD patients versus healthy controls. Abbreviations: MUCCA = mean 
upper cervical cord area, CCV = cervical cord volume, TCV = total cord volume, AUC = 
area under the curve. Adapted from Chien et al., AJNR, 2018 [19]   
 
1.6.2 Evaluation of SC affection in AQP4-IgG+ versus MOG-IgG+ NMOSD patients 
In Study 2 [20], investigating SC affection in AQP4-IgG+ (n = 38) and MOG-IgG+ (n = 15) 
NMOSD patients, we found: 1) a higher history of myelitis and prevalence of SC lesions in 
AQP4-IgG+ NMOSD; and 2) that higher counts of clinical myelitis attacks were associated 
with decreased MUCCA in all NMOSD patients. We could not statistically evaluate the 
effect of treatment on MUCCA in these patients, due to the variety of attack preventing 
therapies given (Figure 3), however, it can be seen that most patients had a decreased 






Figure 3. MUCCA from HC, AQP4-IgG+, and MOG-IgG+ NMOSD patients with associated 
attack preventing therapies. Abbreviations: HC = healthy controls, AQP4-IgG+ = 
aquaporin-4 IgG seropositive NMOSD, MOG-IgG+ = myelin oligodendrocyte glycoprotein 
IgG seropositive NMOSD, MUCCA = mean upper cervical cord area, NA = not 
applicable/unknown. Chien et al., unpublished data. 
 
Finally, MUCCA had associations with clinical disability in both AQP4-IgG+ and MOG-
IgG+ patients as measured by the expanded disability status scale, pyramidal functional 
systems score, averaged timed 25-foot walk and standardized 9-hole peg test (p = 0.030, p = 
0.003, p = 0.010, and p = 0.037, respectively) when age and head-size were taken into 
account [20].  
 
1.6.3 Myelitis attack related changes in the ventral posterior thalamic nuclei in association 
with MUCCA of AQP4-IgG+ NMOSD patients 
In Study 3 [21], we evaluated whether or not the ventral posterior thalamic nuclei (VPN) 
volume in NMOSD patients decreased as a result of clinical myelitis attacks. The mean VPN 
volume was not different (p = 0.730) between age- and sex-matched AQP4-IgG+ NMOSD 
patients (n = 39) and HC (n = 37). No VPN volume differences between a subgroup of 
NMOSD patients with a history of myelitis and HC, nor any associations with the number of 




myelitis-related SC damage, MUCCA was used as a comparator. VPN volume was not 
associated with MUCCA in the entire patient cohort (p = 0.261) or in a subgroup of patients 
with a history of clinical myelitis attacks (p = 0.084). Finally, no correlation was found 
between VPN volume and the sensory functional systems score of the expanded disability 
status scale. However, VPN volume showed a trend to be decreased in patients with a history 
of clinical brainstem attacks versus HC [21]. 
 
1.7 Conclusions and Future Directions 
From the studies conducted for this PhD dissertation, three overarching questions were 
answered: 
1. Can cerebral T1-weighted MRI be used to measure SC atrophy in NMOSD? 
Yes, MUCCA measured from cerebral MPRAGE scans including the upper cervical 
cord is able to reliably evaluate SC atrophy, representative of total cord volume in 
NMOSD. Since MUCCA was able to discriminate between healthy participants and 
NMOSD patients [19], we deemed that this measure can be used to evaluate SC 
atrophy in our multiple sclerosis and NMOSD cohorts in further clinical studies from 
the Charité-Universitätsmedizin Berlin. However, further investigations into the 
longitudinal use of MUCCA must be assessed and tested in a larger cohort, prior to 
using this measure to investigate changes in the SC over time. 
2. Is there a difference in SC affection between aquaporin-4 IgG seropositive (AQP4-
IgG+) and myelin oligodendrocyte glycoprotein IgG seropositive (MOG-IgG+) 
NMOSD patients? 
Yes, there is a difference in SC affection between the two NMOSD subgroups, where 
AQP4-IgG+ NMOSD patients had more SC lesions and atrophy than MOG-IgG+ 
patients. We were able to show that decreased MUCCA is directly associated with an 
increased number of clinical myelitis attacks in both patient subgroups [20]. Thus, our 
findings suggest that there are differences in SC affection between the two antibody 
serostatus groups, which furthers our collective knowledge of attack-related damage 
and common MRI markers that can be used for monitoring patients with AQP4-IgG 
and MOG-IgG associated autoimmunity. Since SC affection is prevalent in both 
patient groups, we will continue to monitor lesions and atrophy in the cord using 
MRI, although it remains to be seen how this information may be used in the clinical 




3. Is there simultaneous atrophy in the ventral posterior nuclei of the thalamus and SC in 
AQP4-IgG+ NMOSD patients with myelitis? 
No, there was no atrophy detected in the thalamic ventral posterior nuclei compared 
to healthy participants, although there was SC atrophy measured by MUCCA in 
NMOSD patients, which is in line with previous studies. This would suggest that CNS 
damage in AQP4-IgG+ NMOSD occurs due to clinical attacks, with higher severity in 
localized regions (i.e. myelitis in the SC causes atrophy in the SC). However, we 
could not completely discount any damage in the thalamic subregions due to clinical 
attacks, since volumetric measurements using 3 Tesla MRI may not have the 
sensitivity to identify microstructural changes, or other disease-related damage 
causing functional or adaptive changes [21]. 
 
Overall, the publications related to this dissertation revealed that MUCCA is a reliable and 
representative measure that is sensitive to SC atrophy in NMOSD. Using SC MRI, we were 
able to elucidate that NMOSD patients with increasing counts of clinical myelitis attacks 
accrue more SC atrophy; and that AQP4-IgG+ patients have a higher prevalence of myelitis 
attacks, SC lesions, and SC atrophy than MOG-IgG+ patients. We did not observe myelitis-
related damage in the ventral posterior nucleus of the thalamus in conjunction with a decrease 
in MUCCA in AQP4-IgG+ NMOSD patients. In conclusion, MUCCA is a parameter which 
can detect NMOSD-related SC damage using 3 Tesla cerebral T1-weighted MRIs, and can be 
used to monitor and quantitatively measure atrophy of the SC in these patients. 
Future directions would include the longitudinal monitoring of SC cross-sectional area in 
NMOSD to evaluate any disease progression or atrophy over time or treatment effects. It 
would also be interesting and beneficial to further investigate thalamic subregional volumes 
using higher magnet strengths (i.e. 7 Tesla MRI) to evaluate changes distal from attack 
regions, which are possibly associated with cognitive impairment.  
In conclusion, the SC MRI quantitative measure investigated in this dissertation was not 
previously used in routine clinical observational studies, was shown to be feasible using a 
common MRI sequence, and is able to give valuable information about localized and overall 
damage in the SC of NMOSD patients. This technique will impact clinical trial planning 
when SC atrophy is a prospective outcome measure and may help us further investigate 
pathophysiological processes, and possibly evaluate patient prognoses and clinical outcomes 
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